Five recently published randomized clinical trials (RCTs)
1-5 demonstrated the superiority of endovascular therapy (EVT) compared with best medical management, including intravenous tissue plasminogen activator (IV tPA) therapy for acute ischemic strokes with large vessel occlusion (LVO) in the anterior circulation. However, the RCTs’ inclusion criteria focused on proximal occlusions involving the distal internal carotid artery and proximal (first segment [M1]) middle cerebral artery (MCA). Patients with more distal occlusions in the second-order branches (M2) of the MCA, however, were underrepresented in the trials. ESCAPE (Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT [Computed Tomography] to Recanalization Times),
2 SWIFT PRIME (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke),
4 and REVASCAT (Randomized Trial of Revascularization With Solitaire FR Device vs Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within 8 Hours of Symptom Onset)
5 restricted enrollment to patients with more proximal occlusions, although a few patients were misclassified as having M1 segment occlusion by the enrolling center and were subsequently adjudicated by the core laboratory as having M2 segment occlusion. MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands)
1 and EXTEND-IA (Extending the Time for Thrombolysis in Emergency Neurological Deficits–Intra-arterial)
3 enrolled only a few patients with distal occlusions. Of 1287 patients enrolled in the 5 trials, only a total of 94 patients were randomized; 51 of these patients received EVT. Evidence from RCTs regarding the benefit of EVT is therefore lacking for M2 segment occlusions, as reflected in the recent American Heart Association guidelines.
6